MedPath

A study of the hematopoietic and iron metabolism effect of epoetin beta pegol on non-dialysis chronic kidney disease patients who do not respond well to darbepoetin alfa by monitoring hepcidin-25.

Not Applicable
Conditions
non-dialysis chronic kidney disease
Registration Number
JPRN-UMIN000009658
Lead Sponsor
Saiseikai yokohama-city tobu hospital
Brief Summary

anemia

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
24
Inclusion Criteria

Not provided

Exclusion Criteria

the patients having allergy for epoetin beta pegol ,erythropoietin and darbepoetin alfa the patients of gastrointestinal hemorrhage the patients having or had liver damages

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of maintaining the target Hb level
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath